Harrow, Inc. - Common Stock (HROW) is currently showing a bullish headline tone with a mixed / range backdrop. The latest news flow is being framed here as context rather than prediction, so beginners can quickly see whether headlines are helping, hurting, or complicating the chart story. Earnings tone is currently no clear earnings read.
HEADLINE TAKE: Higher-value headlines lean meaningfully positive, with stronger signals around growth, upgrades, guidance, or demand.
Change stock
Search another ticker to view its latest news page.
Full chart, indicators and drawing tools on TradingView. Move to Platforms when you are ready to act.
MyStockHarbor.com
NEWS SCORE
69/100
Bullish
Bearish
Neutral
Bullish
Earnings Tone
28
Weak based on actual EPS/revenue
Confidence
Medium
Headline depth
Last Price
$44.24
Trend Context
Mixed / range
Latest briefing
What's happening with HROW
businesswire.com1 Jul 2026
Samsung Bioepis Relaunches BYOOVIZ® (ranibizumab-nuna) in the United States in Partnership with Harrow
INCHEON, Korea--(BUSINESS WIRE)-- #Byooviz--Samsung Bioepis Co., Ltd. today announced the relaunch of BYOOVIZ® (ranibizumab-nuna) in the United States (US), in partnership with Harrow (Nasdaq: HROW). Harrow became responsible for commercialization of BYOOVIZ® (ranibizumab-nuna), a biosimilar referencing LUCENTIS1 (ranibizumab), and OPUVIZ™ (aflibercept-yszy), a biosimilar referencing EYLEA2 (aflibercept), upon full transition of commercialization rights from Biogen back to Samsung Bioepis by the end of 20.
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
globenewswire.com10 Jun 2026
Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare
NASHVILLE, Tenn., June 10, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the re-launch of VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1%, a prescription therapy indicated for the treatment of vernal keratoconjunctivitis (VKC), a serious allergic eye disease that primarily affects children.
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
globenewswire.com27 May 2026
Harrow to Present at William Blair's 46th Annual Growth Stock Conference
NASHVILLE, Tenn., May 27, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will present at William Blair's 46th Annual Growth Stock Conference on Wednesday, June 3, 2026, at 8:40 AM CT, in Chicago, IL.
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
Older updates drop into a lighter feed
globenewswire.com
13 May 2026
HROW Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Harrow for Potential Securities Law Violations
